Health And Fitness

Museveni Lays Foundation Stone For mRNA Vaccine Manufacturing In Wakiso

Museveni Lays Foundation Stone For mRNA Vaccine Manufacturing In Wakiso

Vaccines are one of the most important tools in public health and play an important role in infectious diseases control. Owing to its precision, safe profile and flexible manufacturing, mRNA vaccines are reaching the stoplight as a new alternative to conventional vaccines.

In fact, mRNA vaccines were the technology of choice for many companies to combat the Covid-19 pandemic, and it was the first technology to be approved in both United States and in Europe Union as a prophylactic treatment.

Uganda is poised to join the line of countries that have established active efforts towards development of mRNA vaccines.

Museveni today officially laid a foundation stone for the Biological Drugs and mRNA vaccine manufacturing facility under the Dei Group at Matuga – Wakiso District. He was accompanied by his guest Kenya’s Deputy President H. E. William Ruto.

Dr. Jane Ruth Acheng, Dr. Monica Musenero WHO country Representative Yonas Tegega Woldemariam, Dei Bio Pharmacy Managing Director Mathias Magoola and USA advisor FDA Prof Sarfaraz Niaz were present.

Dei Group of Companies has an growing portfolio of Industries in multiple sectors including Agriculture, Medicine, Technology, Finance and Mining. The Factory deals in pharmaceuticals, research and value addition on produce.

Museveni said in a National address last year that Dei-Pharma would be contracted to make medicines needed in the fight against Covid19 and other diseases.

“Dr. Nambatya is moving ahead, with Government support, to isolate import substances that will help us to fight many viruses. Magoola and Dr. Kyakulaga, now supported by some African Banks such as Equity Bank of Kenya are creating a World class pharmaceutical group, known as Dei-Pharma, that will make any and all the medicines the country needs and even export,” Museveni said on June 3rd 2020.

Messenger RNA (mRNA) vaccines are known for their safety and fast scalability in manufacturing.

Apart from Moderna, Pfizer’s mRNA vaccine was also one of the first commercial COVID-19 vaccines to be approved for use. Never before COVID have mRNA vaccines received authorisation, yet, the scientific know-how which went into their making is what makes them so exciting and much more promising than other vaccines, according to many experts.

The increased demand for mRNA vaccines requires a technology platform and cost-effective manufacturing process with a well-defined product characterisation.

Large scale production of mRNA vaccines consists in a 1 or 2-step in vitro reaction followed by a purification platform with multiple steps that can include Dnase digestion, precipitation, chromatography or tangential flow filtration.

Osbert Mwesigye
Author
Osbert Mwesigye